IBNSINA PHARMA |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.46 EGP | +1.23% |
|
+1.23% | -21.66% |
| 03-03 | Ibnsina Pharma Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 02-05 | Ibnsina Pharma(CASE:ISPH) added to EGX 30 Index | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 58% by 2026.
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
- The stock, which is currently worth 2024 to 0.17 times its sales, is clearly overvalued in comparison with peers.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Ratings chart - Surperformance
Sector: Drug Retailers
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -21.66% | 51.72M | - | ||
| -31.79% | 15.36B | B- | ||
| -23.53% | 12.45B | B | ||
| -25.00% | 6.75B | B | ||
| +9.74% | 6.14B | C | ||
| -10.91% | 6.07B | C+ | ||
| +0.29% | 4.76B | D- | ||
| +59.24% | 4.53B | - | C | |
| -9.00% | 3.81B | B | ||
| -12.53% | 3.43B | C- |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- ISPH Stock
- Ratings Ibnsina Pharma
